| Risk | Moderately High |
|---|---|
| Min SIP Amount | Not Supported |
| Expense Ratio | 2.24% |
| NAV | ₹11.94 (07 Jan 2020) |
|---|---|
| Fund Started | 08 Jul 2016 |
| Fund Size | ₹65 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| ICICI Bank Ltd. | Financial | Equity | 2.0% |
| HDFC Bank Ltd. | Financial | Equity | 1.9% |
| Infosys Ltd. | Technology | Equity | 1.2% |
| GAIL (India) Ltd. | Energy | Equity | 0.7% |
| HCL Technologies Ltd. | Technology | Equity | 0.4% |
| Exide Industries Ltd. | Engineering | Equity | 0.3% |
| GHCL Ltd. | Chemicals | Equity | 0.2% |
| Aurobindo Pharma Ltd. | Healthcare | Equity | 0.2% |
| Cadila Healthcare Ltd. | Healthcare | Equity | 0.2% |
UTI Dual Advantage Fixed Term Fund Series III II (1278 Days) Direct Growth is a Debt Mutual Fund Scheme launched by Axis Mutual Fund. This scheme was made available to investors on 08 Jul 2016. V Srivatsa, Sunil Patil is the Current Fund Manager of UTI Dual Advantage Fixed Term Fund Series III II (1278 Days) Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹65 Cr and the Latest NAV as of 07 Jan 2020 is ₹11.94.
The UTI Dual Advantage Fixed Term Fund Series III II (1278 Days) Direct Growth is rated Moderately High risk.
The scheme seeks to generate income and reduce interest rate volatility by investing in fixed income securities that are maturing on or before the date of maturity of the Scheme and generate capital appreciation by investing in equity and equity related instruments.